Nevertheless, physiological intra-tumor TNF levels are likely insufficient to induce cancer regression in patients; the TNF dosage to have a robust tumor-killing effect without a severe side effect is still a big challenge to reach in clinical trials, and many studies are currently undergoing (18, 19). This evidence concerns the gene TNF and cancer.